__timestamp | Bio-Techne Corporation | TG Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 357763000 | 152381 |
Thursday, January 1, 2015 | 452246000 | 152381 |
Friday, January 1, 2016 | 499023000 | 152381 |
Sunday, January 1, 2017 | 563003000 | 152381 |
Monday, January 1, 2018 | 642993000 | 152000 |
Tuesday, January 1, 2019 | 714006000 | 152000 |
Wednesday, January 1, 2020 | 738691000 | 152000 |
Friday, January 1, 2021 | 931032000 | 6689000 |
Saturday, January 1, 2022 | 1105599000 | 2785000 |
Sunday, January 1, 2023 | 1136702000 | 233662000 |
Monday, January 1, 2024 | 1159060000 |
Cracking the code
In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market influence. Over the past decade, Bio-Techne Corporation has demonstrated a robust upward trajectory, with its annual revenue surging by over 220% from 2014 to 2023. This growth reflects Bio-Techne's strategic innovations and market expansion.
Conversely, TG Therapeutics, Inc. has experienced a more volatile revenue pattern. After years of modest earnings, TG Therapeutics saw a dramatic spike in 2023, with revenue increasing by an astonishing 8,000% compared to 2022. This leap suggests a significant breakthrough or market shift, although data for 2024 remains unavailable.
These contrasting revenue paths highlight the diverse challenges and opportunities within the biotech sector, offering valuable insights for investors and industry analysts alike.
Annual Revenue Comparison: Novo Nordisk A/S vs Bio-Techne Corporation
Revenue Showdown: Pfizer Inc. vs Bio-Techne Corporation
Bristol-Myers Squibb Company vs Bio-Techne Corporation: Annual Revenue Growth Compared
Vertex Pharmaceuticals Incorporated and TG Therapeutics, Inc.: A Comprehensive Revenue Analysis
Takeda Pharmaceutical Company Limited and Bio-Techne Corporation: A Comprehensive Revenue Analysis
Revenue Insights: Bio-Techne Corporation and Amneal Pharmaceuticals, Inc. Performance Compared
Breaking Down Revenue Trends: Bio-Techne Corporation vs ACADIA Pharmaceuticals Inc.
Revenue Insights: Bio-Techne Corporation and Mesoblast Limited Performance Compared
Halozyme Therapeutics, Inc. vs TG Therapeutics, Inc.: Examining Key Revenue Metrics
Revenue Showdown: TG Therapeutics, Inc. vs MorphoSys AG
TG Therapeutics, Inc. and Mesoblast Limited: A Comprehensive Revenue Analysis
TG Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis